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An investigation of changes in ocular blood flow in rabbits
with long-term hyperhomocysteinemia using color doppler
ultrasonography
Figen NARİN1, Abdulhakim COŞKUN2, Nazmi NARİN3, Ali BAYKAN3, Sertaç Hanedan ONAN3,
Abdulkerim COŞKUN4, Muammer Hakan POYRAZOĞLU3, Ruşen EREZ5

Aim: Hyperhomocysteinemia was induced in rabbits using methionine. Ocular blood flow changes were examined by
color Doppler ultrasonography (CDU).
Materials and methods: Fifty New Zealand rabbits were divided into 5 groups. Groups 1-4 received one of the following
chemicals: methionine only, methionine plus vitamin B6, methionine plus vitamin B12, or methionine plus folic acid.
Controls received no chemicals. Serum homocysteine levels were measured on treatment days 1 and 60. Orbital vessels
were examined by CDU on day 60.
Results: In the 4 study groups, homocysteine levels were significantly elevated on day 60 compared to the levels on day
1 (P < 0.05). Elevations of homocysteine levels in group 1 were greater than those of groups 2 and 4 on day 60 (P < 0.05).
When results of ocular blood flow changes were compared, no statistically significant difference was found based on
flow velocities in the ophthalmic artery. Measurements from the ciliary artery revealed a statistically significant decrease
in flow velocity in the study groups (P < 0.05).
Conclusion: Using CDU, we found that flow velocities in the ciliary artery were decreased. This condition is attributed
to atherosclerotic and thromboembolic alterations of the ocular vessels due to hyperhomocysteinemia.
Key words: Homocysteine, atherosclerosis, vitamins, rabbit, color doppler ultrasonography

Uzun dönem hiperhomosisteinemili tavşanlarda oküler kan akımı
değişikliklerinin renkli doppler ultrasonografi ile araştırılması
Amaç: Bu çalışmada, tavşanlara metionin verilerek oluşturulan hiperhomosisteineminin oküler kan akımı üzerindeki
etkilerini renkli Doppler ultrasonografi kullanarak araştırdık.
Yöntem ve gereç: Toplam 50 Yeni Zelanda tavşanı beş gruba ayrıldı. Grup 1-4’e sırasıyla; sadece metionin, metionin ve
B6 vitamini, metionin ve B12 vitamini, metionin ve folik asit uygulandı. Kontrol grubunun diyetine kimyasal madde
eklenmedi. Serum homosistein seviyeleri tedavinin 1. ve 60. günlerinde çalışıldı. Orbital damarlar 60. günde renkli
Doppler ultrasonografi ile değerlendirildi.
Bulgular: Çalışma gruplarının dördünde homosistein seviyeleri 60. günde 1. günden anlamlı şekilde yüksekti (P <
0,05). 60. günde homosistein seviyesindeki yükselme Grup 1’de Grup 2 ve 4’den fazla idi. Oküler arter akım hızlarındaki
değişiklikler karşılaştırıldığında gruplar arasında istatistiksel olarak anlamlı fark gözlenmedi. Çalışma gruplarında silier
arterin akım hızlarında istatistiksel olarak anlamlı düzeyde azalma izlendi (P < 0,05).
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Sonuç: Renkli Doppler Ultrasonografi kullanarak silier arterde kan akım hızlarının azaldığını gösterdik. Bu durum,
hiperhomosisteinemiden dolayı oküler damarlarda gelişen aterosklerotik ve tromboembolik değişiklere dayandırılabilir.
Anahtar sözcükler: Homosistein, ateroskleroz, vitaminler, tavşan, renkli doppler ultrasonografi

Introduction
Homocysteine is a sulfur amino acid produced
by the metabolism of methionine, which is one of
the essential amino acids obtained from dietary
proteins. Homocysteine was found to be one of the
risk factors causing vascular disease when McCully
(1) reported in the 1970s that patients with severe
homocysteinemia died secondary to atherosclerosis
and thromboembolic disease. A mild to moderate
elevation of the serum homocysteine level was
documented as an independent risk factor for
atherosclerosis, peripheral vascular disease, and
cardiovascular disease (2-4).
In evaluating the plasma homocysteine level
and its interaction with conventional vascular risk
factors, the European Concerted Action Project
(2) showed that hyperhomocysteinemia is an
independent risk factor for vascular disease, similar
to smoking or hyperlipidemia. Based on the evidence
of the relationship of elevated plasma homocysteine
levels with atherosclerosis and thromboembolism,
hyperhomocysteinemia was considered as an
additional risk factor for occlusive disease of the
retinal artery and vein and was demonstrated in
several studies (5-7). However, most of these results
are related only to laboratory studies of symptomatic
patients.
Several methods, such as carotid angiography,
fundus fluorescein angiography, laser Doppler
velocimetry, ophthalmoplethysmography, and color
Doppler ultrasonography (CDU) are used to assess
changes in ocular blood flow (8-11). CDU is also
used in the diagnosis of vascular diseases of orbits,
such as arteriovenous malformations, orbital varix,
retinal detachment, diabetic retinopathy, choroid
detachment, ophthalmic arterial stenosis, central
retinal artery and vein occlusion, ocular ischemic
syndrome, and glaucoma (10-13).
In
the
present
study,
we
induced
hyperhomocysteinemia in rabbits by administering
1008

methionine and examined changes in the ocular blood
flow using CDU. We also studied the effects of folic
acid, vitamin B6, and vitamin B12 on homocysteine
levels and ocular blood flow parameters.
Methods
Animals and diets
Fifty (25 female, 25 male) New Zealand rabbits
were divided into 5 groups with 10 rabbits in each.
Only methionine (100 mg/kg per day) was given
to group 1, methionine (100 mg/kg per day) plus
vitamin B6 (30 mg/kg per day) were given to group 2,
methionine (100 mg/kg per day) plus vitamin B12 (80
mg/kg per day) were given to group 3, and methionine
(100 mg/kg per day) plus folic acid (20 mg/kg per
day) were given to group 4 orally as additions to the
diets. Control animals received no chemicals. These
rabbits were followed for 2 months. Weights and
food consumption were recorded weekly. On days 1
and 60 of treatment, rabbits were deprived of food
overnight and blood samples were taken from the
marginal ear vein to measure homocysteine levels.
All experimental protocols were approved by the
Institutional Animal Care and Use Committee of
Erciyes University.
Homocysteine levels were measured by highperformance liquid chromatography (HPLC). HPLC
was performed on a solvent delivery system and a
fluorescent detector (385 nm excitation, 515 nm
emission); 0.1 mol/L acetic acid–acetate buffer, pH
5.5, containing 30 mL/L methanol was used to elute
the constituents as the mobile phase. Flow rate was
0.7 mL/min. L-homocysteine calibrators (5-100 μL
mol/L) were prepared in phosphate-buffered saline,
pH 7.4, and in pooled EDTA plasma. Homocysteine
peaks, which were separated with the analytic HPLC
column, were provided in 3.3 min. Homocysteine
concentrations were calculated according to peak
levels provided from the fluorescent detector. The
variation coefficient was 3.5% (14).
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Evaluation by CDU
All examinations were performed using a CDU
unit (Powervision, Toshiba, Tochigi, Japan) with a 10MHz linear probe. The orbital vessels examinations
were performed on day 60 of treatment. The
rabbits were examined in supine position after an
intramuscular sedative agent was administered.
Ultrasound conductive gel was applied to the external
surface of the eyelids, and care was taken to exert the
least transducer pressure as possible on the closed
eyelids. We first scanned the whole orbit using gray
scale imaging and then applied the CDU with color
scale to identify the orbital vessels.
We determined peak systolic velocity (PSV), enddiastolic velocity (EDV), and resistive index (RI) for
the ophthalmic artery (OA) and the ciliary artery
(CA). PSV was defined as the maximum systolic peak
velocity and EDV was defined as the minimum flow
velocity at the end of the diastolic phase prior to the
next cardiac cycle.
The OA is typically identified as a large caliper
pulsatile vessel adjacent to the optic nerve, showing
an immediate increase in systole followed by a
dicrotic notch and slow diastolic flow. The CA was
both on the nasal (medial) and temporal (lateral)
sides of the optic nerve posterior to the choroid in
their retrobulbar areas.
Statistical analysis
Data are presented as means (±standard
deviations), and the 5 groups were compared using
one-way analysis of variance with t tests for pairwise
comparisons. Shapiro-Wilk test was used for testing

data normal distribution, and found to comply.
The post-hoc Scheffe test was used to compare
differences in proportions among the groups. Data
were analyzed using the SPSS 9.0 (SPSS, Chicago,
IL, USA) software package. P ≤ 0.05 was considered
statistically significant.
Results
Plasma homocysteine levels
Table 1 lists the plasma homocysteine levels.
In all 4 study groups, homocysteine levels were
significantly elevated on day 60 compared to those
on day 1 (P < 0.05). In group 1, elevations of the
homocysteine levels were higher than those of groups
2 and 4 on day 60 (P < 0.05). In group 4, the decrease
of homocysteine levels was significantly lower than
that of groups 1, 2, and 3 on day 60 (P < 0.05).
CDU findings
Table 2 contains the CDU findings. When the
results were compared, no statistically significant
difference was observed between flow velocities
in the OA (P > 0.05). However, the measurements
of flow in the CA in the study groups showed a
statistically significant decrease in flow velocities
(P < 0.05). PSV in group 1 was lower than that in
group 4 and controls (P < 0.05). Although the PSV
in groups 2 and 3 was lower than that in group 4
and controls, the difference was not statistically
significant (P > 0.05). EDV in groups 1 and 3 was
significantly lower than EDV measured in group 4
(P < 0.01). Similarly, EDV of group 2 was lower than
that in group 4 and controls, but this difference was

Table 1. Homocysteine levels in the treatment groups on days 1 and 60 of treatment.
Day 1, μmol/L

Day 60, μmol/L

P

Group 1

9.906 ± 4.226

104.250 ± 53.32

< 0.05

Group 2

9.513 ± 4.075

65.873 ± 14.89a

< 0.05

Group 3

8.355 ± 4.091

84.922 ± 17.35

< 0.05

Group 4

8.615 ± 5.227

19.033 ± 8.825a,b,c

< 0.05

a

Statistically significant compared to group 1 (P < 0.05).
Statistically significant compared to group 2 (P < 0.05).
c
Statistically significant compared to group 3 (P < 0.05).
b
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Table 2. Velocity measurements (cm/s) in orbital vessels.
Vessels

Group 1

Group 2

Group 3

Group 4

Control

F

P

PSV

14.6 ± 3.6

12.1 ± 0.9

14.1± 3.0

15.0 ± 3.0

12.7 ± 3.9

0.9

0.43

EDV

8.3 ± 2.5

6.9 ± 0.6

7.8 ± 2.5

8.9 ± 2.2

7.1 ± 2.8

0.9

0.42

0.42 ± 0.09

0.43 ± 0.03

0.45 ± 0.10

0.40 ± 0.09

0.42 ± 0.09

0.3

0.82

PSV

18.7 ± 3.6*d

23.7 ± 3.9

19.6 ± 5.2

27.7 ± 6.3*e

26.8 ± 6.3*da

5.0

0.03

EDV

10.5 ± 2.7*d

11.8 ± 2.6

11.3 ± 4.5* d

20.1 ± 4.9*ac

17.6 ± 7.6

5.8

0.01

RI

0.44 ± 0.07

0.50 ± 0.05* d

0.40 ± 0.10

0.28 ± 0.02*b

0.36 ± 0.17

4.1

0.08

OA

RI
CA

Each group had 10 eyes examined. Results expressed as velocity (cm/s) ± SD.
Note: “a” refers to the group that is statistically different from group 1; “b” is the group that is statistically different from group 2; “c” is
the group that is statistically different from group 3; “d” is the group that is statistically different from group 4; and “e” is the group that
is statistically different from controls.
*P < 0.05 indicates statistical significance.
OA, ophthalmic artery; CA, ciliary artery; PSV, peak systolic velocity; EDV, end-diastolic velocity; RI, resistive index.

not statistically significant. RI values of the CA in the
first 3 groups were higher than those in group 4 and
controls; however, statistical significance was present
only between groups 2 and 4 (P < 0.05).
Discussion
High levels of plasma homocysteine are toxic
to the vessels. The exact mechanism by which
homocysteine affects the vascular system is poorly
understood. Numerous studies have documented
that hyperhomocysteinemia is a risk factor for both
arteriosclerosis and venous thrombosis (2,3,15-18).
Because the central retinal vein shares a common,
fibrous adventitia with the central retinal artery,
it is likely that both arterial and venous disease
could contribute to the development of a central
retinal vein occlusion. Any sclerotic thickening of
the central retinal artery could easily compress the
adjacent central retinal vein and begin the sequence
of events that leads to thrombus formation (19). As
a risk factor for both arterial and venous disease,
hyperhomocysteinemia may represent a “double hit”
in the multifactorial pathogenesis of central retinal
vein occlusion (20).
1010

Several studies demonstrated that an elevated
plasma homocysteine level is a risk factor for
thromboembolism in ocular vascular structures (57). In 1993, Wenzler et al. (21) described data on 4
patients with central retinal artery occlusion and 2
with central retinal vein occlusion who had elevated
homocysteine levels after methionine-loading
testing. Biousse et al. (22) presented data on a 24-yearold man with bilateral central retinal vein occlusion
and increased plasma homocysteine levels suggested
that elevated homocysteine is an independent risk
factor for retinal vascular occlusive disease (23,24).
Vine et al. (7) demonstrated that a statistically
significant association exists between the presence
of hyperhomocysteinemia and central retinal vein
occlusion. Their study adds further support for a
cardiovascular risk profile for persons with central
retinal vein occlusion. They suggested that all
patients with central retinal vein occlusion should be
screened for possible hyperhomocysteinemia. Unlike
other risk factors, hyperhomocysteinemia is readily
reversible in most individuals by treatment with
inexpensive vitamin preparations containing folic
acid (25,26).
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Although the rabbit retinal vasculature is
quite different from the human retinal vessels, in
this study, we induced hyperhomocysteinemia
in rabbits and assessed the effects of oral vitamin
supplementation (vitamins B6 and B12, and folate) on
hyperhomocysteinemia. Folic acid supplementation
clearly reduced plasma homocysteine levels, whereas
vitamin B12 was less effective and vitamin B6 had
no effect. The results of this study indicate that
supplementation with physiologic doses of folic acid
could reduce homocysteine levels. Our findings were
similar to those reported in other studies (27,28).
In this study, the effects of hyperhomocysteinemia
on ocular blood flow in rabbits were determined
using CDU. We also assessed whether folic acid is
effective on hyperhomocysteinemia as examined
in several studies and whether vitamins B6 and B12
have any impact on the blood flow rates in vascular
structures. The results showed, significantly,
that hyperhomocysteinemia leads to an obvious
reduction in CA flow rates. Oral supplementation
with vitamins B6 and B12 cannot eliminate this
effect. However, oral supplementation with folic
acid plus methionine can prevent the decrease in
flow rates. In this study, supplementation of folic
acid through the diet led to a significant reduction
in homocysteine levels compared to the groups given
vitamins B6 and B12, which is in agreement with the
literature. No significant difference was found in
blood homocysteine levels between groups given
only vitamin B6 or B12 and methionine. Similar to
the laboratory findings, a significant difference was
not observed in CDU and CA flow rates in rabbits
given vitamins B6 and B12 compared to rabbits in
group 1. Our study indicated that, when all the
groups were compared with the control group and
each other, no statistically significant difference
in OA flow rate was found between the group in
which hyperhomocysteinemia was induced by the
administration of only methionine and each of 3
groups given vitamin supplementation.

However, the decrease of some flow parameters in
CA in the study groups was statistically significant,
which could be explained by the possible effect
of small vessels rather than the large ones in
hyperhomocysteinemia.
This was no surprise to us because one of the
essential points in planning this study was the
indication whether hyperhomocysteinemia, which
was shown to be a risk factor for thromboembolic
events in central retinal artery and veins in human
studies as reported in the literature, causes alterations
in flow rates. With such a result, not only will the
findings in clinical studies be supported, but also the
involvement of the central retinal artery and vein will
be determined in cases with hyperhomocysteinemia
during the pre-symptomatic period; this was thought
to be a guide for the treatment of this case, which
is reversible with vitamin supplementation. As
expected, this difference was observed.
In the light of all these findings, the fact that
the involvement of CA, particularly the ocular
involvement in pre-symptomatic cases, might be a
criterion for the evaluation of risk factors and require
further investigation. The CDU used in different
clinical studies of hyperhomocysteinemia revealed
deterioration in the elasticity of vascular structures.
This might suggest that the CA is involved with other
vascular structures. However, this issue needs to be
clarified by further studies.
Using CDU, we demonstrated the hemodynamic
changes associated with hyperhomocysteinemia, that
is, decreased flow velocities in the CA. As indicated,
detailed longitudinal studies must be initiated to
confirm the close association between changes in
blood flow and elevation of plasma homocysteine
levels. Further studies may clearly show the beneficial
effects of vitamin supplementation on the retrobulbar
blood supply in patients with hyperhomocysteinemia.
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